ChromaDex Q4 revenue $21.0M (+18% YoY), Adj EBITDA turns positive at $0.4M

Niagen Bioscience, Inc.

Q4 net sales $21.0M (+18% YoY); Tru Niagen sales $16.1M (+14% YoY).
Net loss narrowed to $1.4M ($0.02 loss per share) from $5.3M loss a year ago.
Adjusted EBITDA profit $0.4M, a $3.8M improvement vs Q4 2021 loss.
Full year net sales $72.0M (+7%); net loss $16.5M, improved $6.6M YoY.
Signed long-term supply deal with Nestlé Health Science; entered China via Sinopharm Xingsha.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Niagen Bioscience, Inc. reported financial results for fourth quarter and the year ended December 31, 2022.

Period: fourth quarter and the year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 8, 2023, ChromaDex Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and the year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-006972

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.